title: Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
abstract: The interaction between tumor cells and the tumor microenvironment is essential in the development and progression of diffuse large B-cell lymphoma (DLBCL). Loss of human leukocyte antigen DR (HLA-DR) in DLBCL is a robust adverse prognostic marker. We evaluated the immunohitochemical expression of HLA-DR in lymphoma and the biologic implications of the loss of HLA-DR. The loss of HLA-DR correlated with clinical stage (p < 0.05), International Prognosis Index (p < 0.05), soluble interleukin-2 receptor (p < 0.05) and poor outcome in patients with DLBCL, especially among elderly patients. Flow cytometry analysis of the infiltrating T-cells showed that the mean CD4 + CD25 +/CD8 ratio of the infiltrating T-cells was higher in the HLA-DR positive group than in the HLA-DR negative group (p < 0.05). These data suggest that loss of HLA-DR expression in DLBCL decreases the ratio of helper T-cell within the T-cell population in the tumor microenvironment and might contribute to escape from immunosurveillance.
authors: a Department of Pathology , Saitama , Japan.
authors: Morihiro
authors: M
authors: Higashi
authors: b Department of Hematology , Saitama Medical Center, Saitama Medical University , Saitama , Japan.
authors: Michihide
authors: M
authors: Tokuhira
authors: a Department of Pathology , Saitama , Japan.
authors: Satoshi
authors: S
authors: Fujino
authors: a Department of Pathology , Saitama , Japan.
authors: Takahisa
authors: T
authors: Yamashita
authors: a Department of Pathology , Saitama , Japan.
authors: Keiko
authors: K
authors: Abe
authors: a Department of Pathology , Saitama , Japan.
authors: Eiichi
authors: E
authors: Arai
authors: b Department of Hematology , Saitama Medical Center, Saitama Medical University , Saitama , Japan.
authors: Masahiro
authors: M
authors: Kizaki
authors: a Department of Pathology , Saitama , Japan.
authors: Jun-ichi
authors: J
authors: Tamaru
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D005260:Female; D015870:Gene Expression; D006684:HLA-DR Antigens / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D016130:Immunophenotyping; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010641:Phenotype; D011379:Prognosis; D016019:Survival Analysis; D059016:Tumor Microenvironment / Q000235:genetics / Q000276:immunology; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006684:HLA-DR Antigens
keywords: Diffuse large B-cell lymphoma; HLA-DR; tumor microenvironment